A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Bristol-Myers Squibb
Arcus Biosciences, Inc.
Pfizer
Pfizer
AstraZeneca
Tyligand Pharmaceuticals (Suzhou) Limited
NuCana plc
M.D. Anderson Cancer Center
SWOG Cancer Research Network
Jiangsu Hansoh Pharmaceutical Co., Ltd.
ImmunityBio, Inc.
Amphia Hospital
Canadian Cancer Trials Group
Cantargia AB
University of California, San Francisco
Incyte Corporation
Tarveda Therapeutics
AstraZeneca
Gilead Sciences
Stanford University
Ziekenhuis Oost-Limburg
National Institutes of Health Clinical Center (CC)